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ABSTRACT
BackgroundMutations in the transient receptor potential channel 6 (TRPC6) gene are associated with an
inherited form of FSGS. Despite widespread expression, patients with TRPC6 mutations do not present
with any other pathologic phenotype, suggesting that this protein has a unique yet unidentified rolewithin
the target cell for FSGS, the kidney podocyte.
Methods We generated a stable TRPC6 knockout podocyte cell line from TRPC6 knockout mice. These
cells were engineered to express wild-type TRPC6, a dominant negative TRPC6mutation, or either of two
disease-causing mutations of TRPC6, G109S or K874*. We extensively characterized these cells using
motility, detachment, and calpain activity assays; immunofluorescence; confocal or total internal reflection
fluorescence microscopy; and western blotting.
ResultsCompared with wild-type cells, TRPC62/2 podocytes are less motile and more adhesive, with
an altered actin cytoskeleton. We found that TRPC6 binds to ERK1/2 and the actin regulatory proteins, caldes-
mon (a calmodulin- and actin-binding protein) and calpain 1 and 2 (calcium-dependent cysteine proteases that
control the podocyte cytoskeleton, cell adhesion, andmotility via cleavage of paxillin, focal adhesion kinase, and
talin). Knockdown or expression of the truncated K874* mutation (but not expression of the gain-of-function
G019S mutation or dominant negative mutant of TRPC6) results in the mislocalization of calpain 1 and 2 and
significant downregulation of calpain activity; this leads to altered podocyte cytoskeleton,motility, and adhesion
—characteristics of TRPC6 2/2 podocytes.
Conclusions Our data demonstrate that independent of TRPC6 channel activity, the physical interaction
between TRPC6 and calpain in the podocyte is important for cell motility and detachment and
demonstrates a scaffolding role of the TRPC6 protein in disease.
JASN 30: 1910–1924, 2019. doi: https://doi.org/10.1681/ASN.2018070729
FSGS is a devastating form of nephrotic syn-
drome.1,2 The cause of primary FSGS is still un-
known but inherited forms of the disease are now
providing revolutionary clues to the underlying
pathogenesis and the target of damage, the glomer-
ular podocyte.3 Transient receptor potential chan-
nel 6 (TRPC6) is a widely expressed, nonselective
cation channel. Mutations in TRPC6 are associated
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with an inherited form of FSGS4–6 and upregulation of TRPC6
expression has been identified in a number of acquired
forms of proteinuric kidney diseases.7 TRPC6 interacts with
the podocyte-specific proteins nephrin and podocin, both of
which have been shown to regulate its activity and/or locali-
zation. Indeed, podocin has been reported to have opposing
effects on the gating of TRPC6 channels evoked by mem-
brane stretch or diacylglycerol.8,9 The mutant forms of
TRPC6 have been shown to activate NFAT-dependent tran-
scription in vitro via calcium influx and activation of calci-
neurin and to regulate the activity of ERK.10–12 TRPC6 has
been shown to have several functions in the podocyte. The
TRPC6 agonist angiotensin II (AngII) increases podocyte
motility.13 Nephrin, which has a role in podocyte adhesion,
has been shown to inhibit TRPC6 activation, and some
disease-causing mutants have decreased nephrin-binding ca-
pability.8 TRPC6 associates with the podocyte actin cytoskel-
eton and there is strong evidence that TRPC6 directly affects
podocyte signaling and cytoskeletal organization in these
cells.14–16 Indeed, recently TRPC6 activity has been linked
to increased calpain 1 and calcineurin activity leading to po-
docyte injury.17
FSGS-causing TRPC6mutations, for example, G109S, have
traditionally been reported to be gain of function, and this
increased calcium conductance is thought to be responsible
for pathology.6 However, several reported disease-causing
mutations show no change in, or even decreased, calcium
conductance.18 For example, the K874STOP (K874*) muta-
tion results in a 57-amino-acid deletion in the C terminus
but has no effect on calcium conductance.4 This suggests
that changes in calcium conductance may not be the sole
mechanism underlying the pathology. Patients with TRPC6
mutations do not present with any other pathologic pheno-
type, suggesting that this protein has a singular role within the
podocyte which is affected by mutation. Therefore, the most
conspicuous question is, what is unique about TRPC6 activity
in the podocyte, a cell that is highly dependent on a tightly
regulated actin cytoskeleton?19
In this study we have developed TRPC6 knockout podo-
cytes from TRPC6 KO mice and used them together with
expression of either GFP-tagged wild-type (WT), dominant
negative (DN), or the G109S and the K874* disease-causing
mutant forms of the receptor to identify novel binding
partners of TRPC6 and explore how the mutations alter
these interactions and protein activity.
METHODS
TRPC6 KO Cell Line and TRPC6 Constructs
Conditionally immortalized control and TRPC6 KO podocyte
cell lines were made as previously described.20
A GFP tag was inserted into the second extracellular
loop of aWT TRPC6 construct in a pcDNAvector after amino
acid 561 using site-directed mutagenesis. PCR was used to
introduce complementary restriction enzyme sites at amino
acid 561 of TRPC6 and both ends of the GFP sequence.
The constructs were then restriction digested and GFP was
ligated into the TRPC6 construct. GFP integration was con-
firmed by sequencing (MWGEurofins, Germany). The G109S
and K874* and the DN TRPC6 LFW678–680AAA21 muta-
tions were introduced into the WT TRPC6-GFP construct
through site-directed mutagenesis and confirmed through
sequencing. All constructs were subcloned into a lentiviral
vector (pWPXL, a gift from Didier Trono [Addgene plasmid
# 12257]) for stable expression in the T6K cells. This construct
was transfected into HEK 293 cells along with packaging vec-
tors pMDG.2 and psAX2 (pMD2.G and psPAX2 were gifts
from Didier Trono [Addgene plasmids # 12259 and #
12260]) to produce virus. T6K podocytes were transduced
with the virus and 8 mg/ml polybrene overnight. Expres-
sion was confirmed through fluorescence microscopy and
western blotting.
Electrophysiology
Whole-cell patch-clamp recordings were performed at
room temperature using patch pipette solution containing
(mM): 115 CsCl, 10 EGTA, 2 MgCl2, 5 Na2ATP, 0.1 NaGTP,
10 HEPES, and 5.7 CaCl2; pH was adjusted to 7.2 with
CsOH. The standard bath solution contained (mM): 130
NaCl, 5 KCl, 8 D-glucose, 10 HEPES, 1.2 MgCl2, and 1.5
CaCl2; the pH was adjusted to 7.4 with NaOH and was
perfused at a flow rate of 2–3 ml/min. Cells were voltage
clamped at 260 mV. TRPC6 was activated through perfu-
sion of 10 mM AngII into the recording chamber. Series
resistance (Rs) was monitored throughout the experiment
and cells showing a.20% change in Rs were excluded from
analysis. Recordings were carried out using a MultiClamp
700B amplifier (Axon Instruments, Foster City, CA). On-
line electrophysiology data acquisition and analysis were
performed using WinLTP software. The holding current
(Ihold) was recorded at 30-second intervals, and the change
in Ihold measured as the difference in the current required
to maintain the holding voltage before Ang II perfusion. All
data were normalized to the mean of the pre–drug perfu-
sion baseline.22 Averaged data from each experimental
Significance Statement
Mutations in the transient receptor potential channel 6 (TRPC6)
gene are associated with an inherited form of FSGS. Emerging ev-
idence has linked TRPC6 activity with calpain activation and
podocyte injury. In this study, the authors generated a TRPC6
knockout podocyte cell line from TRPC6 knockout mice, engi-
neering these cells to express wild-type and various mutations of
TRPC6. They show that TRPC6 binds to both ERK 1/2 and calpain,
and is important for the localization of calpain to the cell membrane,
independent of TRPC6 calcium influx. This interaction is vital for cell
motility and detachment and demonstrates a scaffolding role of
TRPC6. These findings suggest that calpain activation and traffick-
ing may be novel therapeutic targets in the treatment of FSGS.
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condition are represented as the mean and SEM. Data were
analyzed using t test.
Calcium Imaging
Calcium influx to podocytes was measured using a Rhod-3 cal-
cium-imaging kit according to the manufacturer’s instructions
(#R10145; ThermoFisher). Cells were seeded into a 96-well plate
and differentiated for 10–14 days. They were incubated with
10 mM Rhod-3 AM+2.5 mM probenecid in the dark for 30
minutes before being washed and incubated in 2.5 mM proben-
ecid for a further 30minutes. Live-cell imaging was performed in
PBS using the INCell Analyzer (GEHealthcare, Amersham, UK)
imaging platform. Quantification was performed using IN Cell
Analyzer work station 3.5 software. A baseline calcium intensity
reading was taken from each cell in the field of view before
addition of AngII at a final concentration of 1 mM. A second
reading was taken 5 seconds after AngII addition and compared
with the first to see the increase in calcium influx in response to
AngII. Cells were defined by locating the DAPI nuclear signal
and looking at a 3-mM collar around the nucleus.
Biotinylation
Podocytes stably expressing WT TRPC6-GFP were biotinylated
to assess membrane expression. Cells were washed with borate
buffer (10 mM boric acid, 154 mMNaCl, 7.2 mMKCl, 7.2 mM
CaCl,2 pH to 8.6) before being incubated with 2mg biotin for 20
minutes. Excess biotin was quenched by washes with 0.192 M
glycine before cells were lysed in 500ml Tris-buffered saline+2%
NP40+protease inhibitor cocktail and incubated with streptavi-
din or control agarose beads for one hour at 4°C. Five washes of
the beads were carried out with PBS, with a one minute spin at
1000xg between each wash. A “total protein” sample was taken
before the incubation. Samples were then detached from the
beads in 4% SDS running buffer and heated to 95°C for 10
minutes before being run on a 10% acrylamide gel and probed
with anti-TRPC6 or anti-CD99 antibodies.
Motility and Detachment Assays
Motility assays were carried out as previously described.23
Briefly, cells were seeded in six-well plates and differentiated
for 10–14 days at 100% confluency. A cross was then
scratched into the monolayer of cells using a pipette tip.
The cross was imaged at 0 and 12 hours postscratch and
the cell infiltration into the cleared area measured using
ImageJ software. The detachment assay was carried out us-
ing a modified version of a previously published protocol.24
Differentiated cells were trypsinized and resuspended in
media at 33105 cells/ml. Then, 50 ml cells was added to
each well of a 96-well plate along with 50 ml PBS. If an
inhibitor was being used, then this was added to the PBS
at 23 concentration. Cells were left for 48 hours to adhere.
Control wells were fixed with 4% paraformaldehyde to
measure 100% attachment. Next, 50 ml trypsin was added
to each experimental well for 2 minutes before washing
with PBS and adding 50 ml FBS to attenuate trypsinization.
Cells were then fixed with 4% paraformaldehyde. After
washing with H2O, cells were stained with 0.1% crystal
violet in 2% ethanol for 60 minutes. After further washes
the dye was solubilized with 100 ml 10% acetic acid and left
on an orbital shaker for 5 minutes. Absorbance was mea-
sured at 570 nm using a plate reader. Results were expressed
as a percentage of 100% attachment of control cells.
Immunofluorescence
Immunofluorescence was performed as described previously.25
Images were captured using a Leica AM fluorescence confocal
microscope or a Leica AM total internal reflection fluorescence
(TIRF) microscopy multicolor system attached to a Leica DMI
6000 inverted epifluorescence microscope equipped with 405-,
488-, 561-, and 635-nm laser lines. All primary antibodies are
listed in the table below.
Coimmunoprecipitation and Proteomics
Cells transduced with either WT, G109S, or K874* TRPC6-
GFP–expressing lentivirus were lysed in TNE buffer (50 mM
Tris, 100 mM NaCl, 0.1 mM EDTA) containing 10% glyc-
erol+1% NP40. GFP and GFP–TRPC6 proteins and interact-
ing proteins were immunoprecipitated using the GFP-Trap
system (Chromotek). Proteins were eluted from beads into
50 ml 4% SDS loading buffer. Samples were separated on Nu-
page 4%–12% precast gels (Invitrogen) and subjected to
LC–MS/MS analysis on an Orbitrap Velos (Thermo) mass
spectrometer as described previously.25–27
Antibodies Used
Calpain Assay
The calpain assay was performed on differentiated podocytes
using a Calpain Activity Assay Kit (ab65308; Abcam). Triton
X-100 (1%) was added to the provided lysis buffer to detect
membrane-associated calpain activity. Briefly, cells were
Antibody Supplier and Catalog Number
TRPC6 Cell Signaling Technology #16716
Caldesmon-1 Cell Signaling Technology #2980
Calpain 1 Cell Signaling Technology #2556
Calpain 2 Cell Signaling Technology #2539S
Calpain 1 Abcam #ab28258
Talin-1 Cell Signaling Technology #4021
Phospho-p44/p42 (ERK1/2) Cell Signaling Technology #4370S
FAK Cell Signaling Technology #3285S
Phospho-FAK (Tyr397) Cell Signaling Technology #8556S
Synaptopodin Santa Cruz #sc-515842
WT1 Cell Signaling technology #13580
Podocin Abcam #ab50339
CD2AP Cell Signaling #5478
Nephrin Acris #BP5030
GFP Sigma #11814460001
CD99 Kind gift from Professor George
Banting University of Bristol.
Plcy2 Cell Signaling Technology #3872S
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seeded into six-well plates and differentiated for 10–14 days.
Cells were lysed in the provided lysis buffer and a BSA assay
was performed to measure protein concentration. Cell lysate
(100 mg) was then loaded into each well of a 96-well plate and
incubated with the provided buffer and calpain substrate.
Control wells were treated with either active calpain (positive
control) or calpain inhibitor (negative control). The plate was
incubated at 37°C in the dark for 1 hour before absorbancewas
measured at Ex/Em=400/505 nm.
Statistical Analyses
All statistics were performed in GraphPad Prism 5.
RESULTS
Expression of a Functional TRPC6 Construct in
Knockout Podocytes
Podocytes were isolated from TRPC62/2 mice, and a condi-
tionally immortalized cell line was established as described
previously.20 The TRPC62/2 cell line (T6K cells) was exten-
sively characterized by demonstrating the expression of podo-
cyte markers (CD2AP, synaptopodin, WT1, podocin, and
nephrin) and the absence of TRPC6 protein (Figure 1A).
The levels of both TRPC3 and 7 did not change in these cells




































































































Figure 1. A GFP tagged TRPC6 construct is functional when expressed in a TRPC6 KO podocyte cell line. (A) Podocyte markers CD2-
associated protein (CD2AP), synaptopodin, Wills tumor protein 1 (WT1), podocin, and nephrin are expressed in TRPC6 knockout (T6K) cells.
TRPC6 is not expressed. (B) A TRPC6 construct with an extracellular green fluorescent protein (GFP) tag at amino acid 561 was generated
and reintroduced to the T6K cells. This is demonstrated by western blotting and immunofluorescence (magenta, actin; GFP, green; DAPI,
blue). Disease-causing and DN forms of the GFP-tagged TRPC6 construct were also generated and introduced to T6K cells. (C and D)
Biotinylation and TIRF microscopy demonstrating that WT TRPC6-GFP was able to traffic to the plasma membrane. CD99 is a membrane
protein and was used as a control in both experiments. (E) Patch clamp analysis of channel function. Pooled data of change in Ihold caused by
6-minute 1 mM AngII perfusion. AngII perfusion causes a rapid change in Ihold in WT (236.2610.5 pA at 8-minute timepoint, open sym-
bols, n=5) but not the null mutant (8.763.4 pA at 8-minute timepoint, closed symbols, n=4) or T6K (23.564.3 pA at 8-minute timepoint,
triangle symbols, n=4) cells. Gray vertical bar represents perfusion of AngII. All symbols represent the mean6SEM. (F) Summary box plot
(boxes, 25th–75th percentile; lines, median) showing changes in Ihold caused by 1 mM AngII perfusion at the 8-minute timepoint in (E).
*P,0.05, unpaired t test. Con, control.
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lentiviral transduction, TRPC6 constructs were stably ex-
pressed in these cells, allowing WT, dominant negative
(DN), and disease-causing mutant forms of TRPC6 to be
studied without interference of any native TRPC6 channels.
Tomonitor expression of these constructs, an internal GFP tag
in the second extracellular loop was added (Figure 1B). There
is no significant known role of the second extracellular loop in
TRPC6 protein function and thus it was determined that tag-
ging here would cause minimal disruption to protein func-
tion. The intracellular N and C termini are known to be
involved in trafficking and protein interaction of the channel,
and a protein tag placed in this region may have prevented
binding. Expression of the GFP-tagged WT TRPC6 construct
was confirmed through immunofluorescence and western
blotting (Figure 1B). Biotinylation and total internal reflection
fluorescence (TIRF) microscopy experiments were also per-
formed to confirm that the construct still trafficked to the
plasma membrane despite the presence of the GFP tag (Figure
1, C and D), comparing with the membrane protein CD99.
Calcium influx in response to 10 mM AngII was measured in
T6K cells and T6K cells expressing either WT (T6K+WT) or
the previously described DN (T6K+DN) TRPC6-GFP con-
struct,21 using rhod-3 calcium imaging and patch clamping,
Experiment Statistical Analysis Unit of Analysis
Patch clamp analysis Unpaired t test Pooled cells
Motility and
detachment





One-way ANOVA Per experiment (three
replicates per
experiment)









Paired t test Per experiment (three wells
imaged per experiment)








































Figure 2. TRPC6 KO cells have altered motility and detachment compared to controls. (A) Motility of the TRPC6 KO (T6K) cell line was
measured by scratch assay closure after 12 hours and compared with control and T6K podocytes expressing WT TRPC6-GFP (T6K+WT).
T6K cells (38.40%67.34% closure) were less motile than control podocytes (73.67%67.56% closure). This was rescued by re-
introduction of WT TRPC6-GFP (72.54%66.82% closure). One-way ANOVA, *P,0.05, **P,0.01. (B) Detachment was measured as cells
lost after 1-minute trypsin treatment. This demonstrated decreased detachment of T6K podocytes (46.35%69.72%) compared with
control and T6K+WT (72.49%61.93% and 80.08%60.95%, respectively). One-way ANOVA, *P,0.05, **P,0.01. (C) There was visible
alteration of the actin cytoskeleton in T6K cells compared with control and T6K+WT podocytes. Magenta, phalloidin staining for actin.
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demonstrating that the expressed WT TRPC6-GFP was func-
tional (Figure 1, D–F, Supplemental Figure 2A) and impor-
tantly that the GFP tag had no significant effect on TRPC6
channel activity compared with an untagged version (Supple-
mental Figure 2B).
Motility and Adhesion Regulated by TRPC6
Podocyte adhesion and motility are often altered in disease
states; therefore, we examined cell motility using a wound
healing assay. The WT podocytes and T6K cells transfected
with TRPC6were significantly moremotile than the T6K cells,
suggesting that the absence of TRPC6 impairs cell motility
(Figure 2A).
Adhesion of the cell to, and detachment of the cell from, the
culture flask was also studied. There was no significant differ-
encebetween the control, T6K, andT6K+WTcells in the ability
of the cell to adhere to the culture flask (data not shown).
However, it was noticed when culturing T6K cells that they
required a much longer incubation with trypsin to detach
from the culture flask. This was verified using a detachment
assay (Figure 2B). The percentage of cells that had detached
from the well after a 1-minute trypsin incubation was deter-
mined, with significantly fewer T6K cells detaching compared
with control or T6K+WT. The decreased motility of T6K cells
observed is therefore likely due to an impairment in the cells’
ability to deadhere, decreasing their ability to move.
Actin remodeling is closely linked to cell motility and ad-
hesion, and actin reorganization is seen with podocyte foot
process effacement.Overexpression of TRPC6has previously
been shown to cause cytoskeletal rearrangement, and inhi-
bition of the receptor has been shown to prevent albumin-
induced F-actin cytoskeletal disruption.7 Control, T6K, and
T6K+WT podocytes were stained with phalloidin and im-
aged on a confocal microscope (Figure 2C). There weremore
actin stress fibers present in the T6K cells, whereas in the
control and T6K+WT podocytes actin was localized to the
membrane and evenly spread throughout the cytoplasm
(Figure 2C).











TRPC6 1 500 500
TRPC7 1 71 71
TRPC3 1 59 59
Calpain 2 1 21 21
Calpain 2 sub 1 20 20
Caldesmon-1 4 36 9















































Figure 3. Calpain 1, calpain 2, caldesmon-1 and ERK 1/2 are novel TRPC6 binding partners. (A) Table of proteomics results of TRPC6-
binding partners from WT human podocytes overexpressing TRPC6-GFP. TRPC6 was seen to bind to TRPC3, TRPC7, and PLCy2,
interactions that have been described previously.49,50 Novel interactions with calpain 2 and caldesmon-1 were identified. Podocytes
expressing the GFP protein only were used as a control. (B) Interactions reported by proteomics were confirmed in TRPC6 KO cells
expressing WT TRPC6-GFP (T6K+WT) by coimmunoprecipitation (TRAP lane). Control agarose beads were used to demonstrate that
immunoprecipitation was specific to TRPC6 (control lane). Additional interactions with calpain 1 and ERK 1/2 were also identified. On
the basis of the proteomics results, the phosphorylation and/or cleavage states of FAK, talin-1, caldesmon-1, and ERK 1/2 were as-
certained through western blotting. (C) T6K had increased FAK phosphorylation at Tyr 397 and decreased ERK phosphorylation
compared with control and T6K+WT cells. (D) Cleavage of FAK, talin-1, and caldesmon-1 was decreased in T6K cells compared with
controls. For densitometry see Supplemental Figure 3. Con, control; TRAP, GFP-TRAP associated pull-down.
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Protein Partners of TRPC6 in Podocytes
To identify novel TRPC6-binding partners, GFP-tagged WT
TRPC6-GFP was expressed in podocytes using lentiviral
transduction. These and control cells, expressing GFP only,
were then lysed and the GFP immunoprecipitated using the
highly efficient GFP-Trap method.28 The precipitated GFP
and TRPC6-GFP were separated by SDS-PAGE and interact-
ing proteins analyzed by LC–MS/MS after in-gel tryptic
digestion. Three intracellular proteins (calpain 2, caldes-
mon-1, and PLCy2) and two ion channel proteins (TRPC3
and TRPC7) were identified by MS analysis, and were sig-
nificantly more abundant in the TRPC6-GFP pulldown
compared with the GFP control (Figure 3A). Coimmuno-
precipitation experiments were performed to verify the
physical interaction of TRPC6 with calpain 2, caldesmon-
1, and PLCy2 (Figure 3B). Immunoprecipitation experi-
ments were also carried out for calpain 1 and ERK 1/2,
proteins that are known to interact with or be linked to those
identified in the proteomic screen, and these proteins were
also shown to interact with TRPC6 (Figure 3B, Supplemen-
tal Figure 3).
Loss of Calpain Activity in TRPC6 KO Cells
The calpains are a family of calcium-dependent proteases and
one of their cleavage targets is focal adhesion kinase (FAK).
Given the roleof FAKinadhesionand the increased adhesionof
the T6K cells, the phosphorylation status of FAK in the control,
T6K, and T6K+WT cells was determined. FAK showed in-
creased phosphorylation in T6K cells when compared with
T6K+WTand control cells at the Tyr 397 autophosphorylation
site (Figure 3C). Because ERK1/2 had also been identified as a
TRPC6-binding protein and is known to form a complex with
FAK and calpain, its phosphorylation was also studied.29 We
demonstrated decreased ERK1/2 phosphorylation in T6K cells
compared with control or T6K+WT podocytes (Figure 3C).
FAK, ERK1/2, and calpain have previously been shown to
form a complex30 and, because all three were coimmunopre-
cipitated with TRPC6, the calpain cleavage targets talin-1,
***
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A BCalpain Activity Assay








































































Figure 4. Calpain activity is decreased in T6K cells and calpain inhibition mimics the TRPC6 KO phenotype. (A) Calpain activity was
decreased in TRPC6 KO (T6K) cells compared with control (42,60968900 A.U. versus 99,49368227 A.U) and recovered to normal
levels (106,13869414 A.U) when WT TRPC6 was reintroduced (T6K+WT). (B) Addition of the calpain inhibitor calpeptin (10 mM) re-
duced motility of control and T6K+WT podocytes by 67.7% and 20.7%, respectively, but had no effect on T6K cell motility. *P,0.05,
***P,0.001, unpaired t test. (C) Addition of the calpain inhibitor calpeptin on detachment. Treatment with 10 mM calpeptin reduced
detachment of control and WT cells by 26.3% and 19.2%, respectively. There was no significant effect on T6K podocytes. (D) In-
cubation of control cells with 10 mM calpeptin inhibited cleavage of calpain targets and led to phosphorylation of FAK. It had no effect
on T6K cells. Unpaired t test, **P,0.01, ***P,0.001. A.U., arbitrary units; Calp, calpeptin; Con, control.
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caldesmon-1, and FAK were probed for (Figure 3D). Each of
these proteins was shown to have increased cleavage in the
control, T6K+WT, and T6K+DN podocytes compared with
T6K, suggesting that the presence of TRPC6 is important for
calpain activity and cleavage of these targets.
Calpain activity assays confirmed a loss of calpain activity
in TRPC6 KO cells compared with T6K+WTand control po-
docytes (Figure 4A). Treatment of control and T6K+WT cells
with the calpain inhibitor calpeptin (10 mM) caused motility
of the cells to mimic that seen in T6K podocytes but had no
effect on the motility of the T6K cells (Figure 4B). Treatment
of these cells with calpeptin also decreased detachment and
blocked cleavage of talin-1, caldesmon-1, and FAK (Figure 4,
C and D). This suggests that the loss of calpain activity is re-
sponsible for the decreased motility and detachment of the
T6K cells. AngII is a TRPC6 agonist and a calcium assay dem-
onstrated that application of AngII to control and T6K+WT
podocytes caused calcium influx into the cell, as shown in
Supplemental Figure 2. Neither AngII nor the TRPC6
inhibitor, SAR 7334,31 had any effect on calpain activity in
control, T6K+WT, or T6K podocytes even though SAR 7334
blocked calcium influx into the cells (Figure 5, A and B, Sup-
plemental Figure 2, C–E). Treatment with the TRP channel
activator OAG also had no effect on calpain activity (Supple-
mental Figure 2F). Furthermore, calpain activity was not al-
tered in cells that expressed T6K+DN (Figure 5C) even though
this mutant bound to calpain (Figure 5D). These results sug-
gest that increased calcium influx does not alter calpain activ-
ity. Calpain binding was also maintained in the presence of
SAR 7334 (Figure 5E).
This ledus tohypothesize that the effect ofTRPC6knockout
on calpain activity was due to altered localization of calpain
rather than decreased calcium influx. This was examined using
immunofluorescence staining and confocal microscopy (Fig-
ure 6A). Calpain 1 appeared to be membrane localized in the
control and T6K+WT cells, but not in the T6K cells. This was
confirmed by TIRFmicroscopy, showing that in the T6K+WT,
T6K+DN, and control cells calpain was visualized at the
















































































































































Figure 5. Decreased calpain activity is independent of calcium influx through TRPC6 activation. (A) Addition of the TRPC6 agonist
AngII (1 mM), which is known to increase calcium current through the receptor (see Figure 2E, Supplemental Figure 2A), had no effect
on calpain activity in control, T6K, or T6K+WT podocytes; unpaired t test. (B) Application of TRPC6 inhibitor SAR 7334 (20 nM) to
control, T6K, or T6K+WT podocytes had no effect on calpain activity; unpaired t test. (C) Calpain activity was at control levels in TRPC6
KO cells expressing a DN mutant and significantly increased compared with T6K (T6K+DN=128,612611,370 A.U.; con-
trol=120,297612,481 A.U.; T6K+WT=129,619610,408 A.U.; T6K=68,97367009 A.U.). *P,0.05, **P,0.01, one-way ANOVA. (D) GFP
TRAP coimmunoprecipitation shows interaction between calpain and TRPC6 in both T6K+WT and T6K+DN podocytes. (E) There was
also an interaction between TRPC6 and calpain in cells that had been treated with the TRPC6 inhibitor SAR 7334. Ang, Angiotensin;
A.U., arbitrary units; Con, control; Lys, lysate.
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plasma membrane of the cell, and this membrane localization
was lost in the T6K cells (Figure 6B). These results suggest that
the interaction between TRPC6 and calpain 1 and 2 is impor-
tant in the localization and activation of calpain.
TRPC6 Mutants and Calpain Membrane Localization
Disease-causing mutations can have varying effects on the
calcium conductance of TRPC6 channels. We investigated
whether altered interaction between TRPC6 and calpain could
be causing the pathology seen in these patients. Two mutants,
G109S,whichhas been reported to cause an increase in calcium
conductance, and K874*, which has no effect on channel con-
ductance, were used.4,6 As expected, the G109S-expressing
podocytes showed increased calcium conductance in response
to 1 mM AngII, whereas there was no effect in the K874*-
expressing cells (Figure 7A, Supplemental Figure 2A). Both
mutants bound ERK 1/2 but there was decreased interaction
between TRPC6 K874* and both calpain 1 and calpain 2,
whereas the interaction was maintained with the G109S mu-
tant (Figure 7B). The G109S mutant cells mimicked WT cells
in their motility, adhesion, protein phosphorylation, and cal-
pain target protein cleavage. In contrast, K874* podocytes
















Figure 6. Calpain localization is altered in T6K podocytes. (A) Confocal microscopy showing the localization of calpain 1 and the
nuclear marker DAPI in control, TRPC6 KO (T6K), and TRPC6 KO expressing WT TRPC6-GFP (T6K+WT) podocytes. Calpain localization
is lost from the membrane in T6K cells, and rescued by the reintroduction of WT TRPC6-GFP. (B) TIRF microscopy showing location of
calpain 1, GFP (for TRPC6-GFP), and actin in control, T6K, and T6K+WT podocytes. TIRF microscopy will only image at or very near the
cell surface. Calpain can be seen at the surface of control cells, T6K+WT cells, and T6K cells expressing the DN mutant (T6K+DN) but
not T6K cells. Fluorescence microscopy has been used on the T6K cells to show that calpain is present in the cell, just not at the surface.
Red, calpain; blue, DAPI; green, TRPC6-GFP; pink, actin, in all images.































A Increase in calcium influx with Ang II








































































































































































Figure 7. The TRPC6 mutant K874* does not bind to calpain and podocytes expressing this mutant have a similar phenotype
to T6K cells. (A) AngII (1 mM) initiates an increase in calcium in control and in all cell types. Calcium increases were 33.7564.7%,
19.0861.6%, 31.2063.8%, 52.5662.8%, and 36.6268.2.6%, for the control, T6K, T6K 1 WT, T6K 1 G109S and T6K 1 K874* po-
docytes, respectively. The calcium increase is significantly larger in the gain-of-function mutant G109S, and significantly smaller in the
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were less motile, more adhesive, and had decreased calpain
activity (Figure 7, C–E).
In the K874* mutant podocytes FAK phosphorylation was
increased and ERK phosphorylation was decreased, and there
was decreased protein cleavage of calpain targets for the K874*
mutant (Figure 7F). The K874* mutant therefore mimics
the TRPC 6KO cells, despite there being no change in
TRPC6 conductance. This suggests that the pathology of the
K874* mutant is via its altered calpain binding.
As with T6K cells, calpain expression in the K874* podo-
cytes was not seen in the membrane using either confocal
(Figure 8A) or TIRF (Figure 8B) microscopy.
DISCUSSION
Mutations in TRPC6, a nonselective cation channel, are asso-
ciated with an inherited form of FSGS. Despite widespread
expression, patients with TRPC6 mutations do not present
with any other pathologic phenotype, suggesting that this pro-
tein has a unique rolewithin the target cell for FSGS, the kidney
podocyte. Although most TRPC6 mutations are reported to
cause changes in calcium dynamics, it is unclear how these
result in a podocyte-specific phenotype, a cell that is highly
dependent on a tightly regulated actin cytoskeleton. To un-
derstand the role of TRPC6 in the podocyte and the effect of
disease-causing mutations, conditionally immortalized TRPC
6KO podocytes were established from TRPC6 KOmice. These
cellswere found tobe lessmotile,more adhesive, and to have an
altered actin cytoskeleton compared with WT podocytes or
knockout podocytes expressing WT TRPC6. This agrees with
previous work showing that TRPC 6KO podocytes are less
motile, and that this phenotype was rescued by reintroduction
of wtTRPC6,13 but is in contrast to other studies that have
reported a role for TRPC6 in inducing Rho activation, stress
fiber formation, and decreased motility.15,32–34 This discrep-
ancy might be due to the level of TRPC6 knockdown because
these cells have been developed from a knockout animal com-
pared with the previous studies using siRNA technology,
where some preservation of expression is seen.
TRPC6 has been shown to interact with several proteins in
the podocyte, including podocin and nephrin.4 This led us to
wonder whether there are other, as yet unidentified, TRPC6
protein interactions that are important in podocyte function.
Using GFP TRAP-pulldown coupled with mass spectrometry
we identified several TRPC6-binding partners, including
TRPC3, TRPC7, and PLC, which are known interactors of
TRPC6, thus validating our approach.8 However, two of the
identified interactors, calpain 2 and caldesmon-1, are novel.
These interactions were confirmed by immunoprecipitation
experiments, which also showed that TRPC6 binds to calpain
1. Because ERK1/2 signaling is known to be required for cal-
pain activation,35 and because gain-of-function TRPC6 mu-
tations have been shown to increase ERK1/2 activation,10 we
also looked to see whether there was a physical interaction
between TRPC6 and ERK 1/2. Importantly, we showed that
ERK 1/2 is also a novel TRPC6 interactor. Whether these are
direct interactions or via a complex with other proteins, such
as seen for podocin for the interaction of TRPC6with NADPH
oxidase, is still to be determined.36
The calpains are a family of calcium-dependent proteases
that have critical functions in controlling the podocyte cyto-
skeleton, and hence cell adhesion and motility, via cleavage of
paxillin, FAK, and talin. An increase in calpain activity has
previously been reported as contributing to puromycin ami-
nonucleoside–induced podocyte injury.37 Furthermore,
cleavage of talin-1 by calpain has also been hypothesized to
promote the pathogenesis of nephrotic syndrome, and calpain
1 has recently been shown to link TRPC6 activity to podocyte
injury.17,38 In neuronal cells and tissue activation of calpain
has been reported to lead to TRPC6 degradation, contributing
to neuronal damage in cerebral ischemia.39–41 Calpain activity
was significantly downregulated in the TRPC6 knockout cells
and treatment of control and T6K+WT cells with the calpain
inhibitor calpeptin resulted in decreased motility in the con-
trol and T6K+WT cells, mimicking that seen in TRPC6
knockout podocytes. This suggests that the loss of calpain
activity is responsible for the decreased motility of the
TRPC6 knockout cells. Importantly, although treatment of
the control and T6K+WT podocytes but not the TRPC6
knockout cells with AngII caused calcium influx into the
cell, there was no effect of treatment on calpain activity. These
data indicate that the regulation of calpain activity by TRPC6
is independent of alterations in its calcium conductance. In-
terestingly, TRPC6 activity has recently been linked to in-
creased calpain 1 and calcineurin activity leading to podocyte
injury.17 However, in contrast to our data this study demon-
strated calpain activation upon treatment of mouse podocytes
with Adriamycin or the TRP channel activator OAG,17 sug-
gesting that the mode of calpain activation requires further
study.
Knockdown of TRPC6 or expression of the K874*, but not
the G109S or TRPC6DN mutant, resulted in increased FAK
phosphorylation and decreased ERK phosphorylation. It can
TRPC6 KO podocytes (T6K). One-way ANOVA, *P,0.05, **P,0.01, ***P,0.001. (B) Coimmunoprecipitation shows that calpain 1 and 2
bind to WT and G109S TRPC6 but not K874*. TRAP lane shows protein eluted from TRAP beads; control lane shows protein eluted from control
beads. ERK1/2 binds to all three TRPC6 constructs. (C–E) Motility, detachment, and calpain assays for control, T6K, WT, and mutant podocytes.
K874* mimicked T6K, whereas G109Smimicked control andWT cells. Values are given in the table in (F). (F) Summary table of values for motility,
detachment, andcalpainactivity. (G)Phosphorylationandcleavageof control, T6K,WT,andmutantpodocytes.K874*mimicsT6K,whereasG109S
mimics WT. For densitometry see Supplemental Figure 3. *P,0.05, **P,0.01, ***P,0.001. A.U., arbitrary units; Con, control; Lys, lysate.















Figure 8. K874* podocytes do not bind to calpain and have a similar phenotype to T6K cells. (A) Confocal microscopy showing lo-
calization of calpain 1. Calpain 1 shows some membrane localization in control and WT or G109S TRPC6 expressing TRPC6 KO
podocytes (T6K+WT) or (T6K+G109S) cells, but not in T6K or T6K+K874*. GFP has been used to confirm presence of TRPC6 in
transfected cells. (B) TIRF microscopy supported this loss of membranous calpain in T6K and K874* cells. Membranous calpain was
seen in all other cell types. For all images, red, calpain; green, TRPC6-GFP; pink, actin.
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therefore be deduced that TRPC6 is contributing to the phos-
phorylation state of ERK1/2 and FAK. Src-induced phosphor-
ylation of FAK has been shown to be required for rapid actin
stress fiber assembly and focal adhesion formation. It is also
required for the formation of a calpain–FAK–ERK1/2 complex
and calpain cleavage of FAK.42 Furthermore, it has previously
been shown that there is an increase in ERK1/2 phosphoryla-
tion in podocytes expressing gain-of-function disease-causing
TRPC6 mutations.10 In addition, ERK phosphorylation has
been shown to increase calpain activation43 and cell motil-
ity.44–46 Knockdown of TRPC6 or expression of the K874*mu-
tant also led to decreased cleavage of the calpain targets talin-1,
caldesmon-1, and FAK, suggesting that the presence of TRPC6
is important for calpain cleavage of these targets. The cleavage
of FAK leads to deadhesion and motility of cells and talin-1
cleavage has been demonstrated to be a rate-limiting step in
adhesion disassembly,47 so decreased cleavage of these proteins
is consistent with the increased adhesion, decreased motility,
and actin reorganization observed in the T6K and K874* mu-
tant podocytes. Again, the lack of effect of the DN and G109S
mutants on calpain activity and cleavage of target proteins sug-
gests that increased calcium conductance is not important
in the regulation of calpain by TRPC6. Confocal and TIRF
microscopy of these cells demonstrated a mislocalization
of calpain away from the plasma membrane, suggesting that
interaction of calpain with TRPC6 is critical for its correct
localization and regulation. These data support the idea that




























Figure 9. Proposed role of the calpain-TRPC6 interaction in podocytes. (A) WT TRPC6 binds to, and acts as a structural scaffold at the
membrane for, caldesmon-1 (cald1), ERK 1/2, and calpain. This keeps calpain localized just below the membrane where it can easily
cleave its targets talin-1, FAK, and caldesmon-1. (B) In the absence of TRPC6 there is no calcium influx to the cell and calpain is also not
localized to the membrane. This means that there is no cleavage of talin-1, FAK, or caldesmon-1. (C) The disease-causing mutant
TRPC6 K874* has a truncation at its C terminus. Calpain no longer binds to this form of TRPC6 and is mislocalized. The mutant allows
the same calcium influx as WT TRPC6. There is no cleavage of caldesmon-1, talin-1, or FAK. This suggests that the localization of
calpain to the membrane is important in its function in the podocyte.
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calpains is an important driver in the pathogenesis of FSGS, as
highlighted in the summary schematic (Figure 9).48
Overall, this study shows that TRPC6 plays an important
role in themotility and adhesion of podocytes, achieved in part
through its physical interaction with calpain 1 and 2, indepen-
dent of any alteration in calcium conductance, providing a new
mechanism for disease pathogenesis in FSGS.
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